Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-5 (2021)
Introduction We present seven cases of infectious keratitis after corneal crosslinking (CXL) to attenuate keratoconus progression. Methods Of 524 consecutive patients who underwent CXL, 7 cases (4 males and 3 females; 21.5 ± 7.1 years) developed pos
Autor:
Hamed Radmehr, Alireza Dehghani, Farzan Kianersi, Afsaneh Naderi Beni, Pegah Noorshargh, Mohammadreza Akhlaghi
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-8 (2021)
Background One of the major side effects of Hydroxychloroquine (HCQ) is retinopathy. The aim of this study was to evaluate the Optical coherence tomography angiography (OCTA) parameters in a group of patients who have Hydroxychloroquine-induced retin
Autor:
Abdoulaye Napo, Serge Resnikoff, Abba Kaka Hadja Yakoura, Michel Gouda, Fatoumata Sylla, Robert C. Della Rocca, Seydou Bakayoko, LI Traoré, Rodrigue Romulad Elien, Nouhoum Guirou
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-4 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-4 (2021)
Background Ocular damage, including damage to the conjunctiva, lacrimal gland, eyelids, and orbit, caused by Schistosoma haematobium is sporadic. We report a clinical case of orbital migration of schistosome eggs. Case presentation A 14-year-old boy
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-7 (2021)
BackgroundThe treatment efficacy of botulinum toxin bilateral medial rectus injections for acute acquired concomitant esotropia (AACE) in adult is not clear. We characterize the effects of botulinum toxin injection in the treatment of AACE, especiall
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
Background Numerous cytokines have been proven to participate in the pathogenesis of neovascular age-related macular degeneration (nAMD). The present study aimed to investigate the aqueous humor cytokine expression profile in nAMD patients before and
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-8 (2020)
Background The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab and bevacizumab in diabetic macular edema (DME). Post -hoc analyses showed that after a 12-week
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-9 (2020)
Background It is not clear whether macular laser combined with anti-vascular endothelial growth factor (VEGF) can reduce the number of anti-VEGF injections in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Our
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
Background The development of ghost cell glaucoma in patients with proliferative diabetic retinopathy (PDR) after intravitreous injection (IV) was rare. Here we reported a series of patients with PDR who received Intravitreous Ranibizumab (IVR) and d
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-5 (2020)
Background To report a bilateral cystoid macular edema associated with Henoch-Schonleinpurpura. Case presentation A 21-year-old man presented a bilateral, painless, and bilateral blurred vision for 5 weeks with visual acuity (VA) of 6/12 on the right
Autor:
Justus G. Garweg, Boris Gekkiev, Giovanni Staurenghi, Bianca S. Gerendas, Philippe Margaron, Wayne Macfadden, Petr Kolar, Cornelia Dunger-Baldauf
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-11 (2020)
Background To evaluate the efficacy and safety of two individualized ranibizumab retreatment schemes in neovascular age-related macular degeneration. Methods Patients (N = 671) were randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg